GW&K Investment Management LLC Sells 42,063 Shares of Medpace Holdings, Inc. $MEDP

GW&K Investment Management LLC cut its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 21.2% in the fourth quarter, HoldingsChannel reports. The firm owned 156,198 shares of the company’s stock after selling 42,063 shares during the period. Medpace comprises about 0.8% of GW&K Investment Management LLC’s investment portfolio, making the stock its 20th largest holding. GW&K Investment Management LLC’s holdings in Medpace were worth $87,733,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of MEDP. Optiver Holding B.V. bought a new stake in Medpace during the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace during the 4th quarter valued at $30,000. Elyxium Wealth LLC bought a new stake in Medpace during the 4th quarter valued at $30,000. Finally, Quarry LP bought a new stake in Medpace during the 3rd quarter valued at $35,000. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is owned by insiders.

Medpace Trading Up 1.9%

Shares of NASDAQ:MEDP opened at $466.79 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $294.07 and a 12-month high of $628.92. The business’s fifty day simple moving average is $456.86 and its 200-day simple moving average is $506.57. The company has a market capitalization of $13.33 billion, a PE ratio of 29.34, a P/E/G ratio of 2.32 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period last year, the business posted $3.67 EPS. The business’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MEDP. BMO Capital Markets decreased their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Truist Financial cut their price target on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and cut their price target for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Robert W. Baird cut their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $467.08.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.